CA2603847A1 - Anticorps anti-psma conjugues - Google Patents

Anticorps anti-psma conjugues Download PDF

Info

Publication number
CA2603847A1
CA2603847A1 CA002603847A CA2603847A CA2603847A1 CA 2603847 A1 CA2603847 A1 CA 2603847A1 CA 002603847 A CA002603847 A CA 002603847A CA 2603847 A CA2603847 A CA 2603847A CA 2603847 A1 CA2603847 A1 CA 2603847A1
Authority
CA
Canada
Prior art keywords
antibody
dota
radioisotope
meo
psma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002603847A
Other languages
English (en)
Inventor
John L. Tedesco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytogen Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2603847A1 publication Critical patent/CA2603847A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne de nouvelles compositions, des méthodes de traitement du cancer, des méthodes de diagnostic du cancer, des compositions pharmaceutiques et des méthodes pour fabriquer des anticorps conjugués comprenant un anticorps qui se lie immunospécifiquement à l'antigène de la membrane spécifique à la prostate et est conjugué à un radio-isotope par une liaison MeO-DOTA.
CA002603847A 2005-04-08 2006-04-10 Anticorps anti-psma conjugues Abandoned CA2603847A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US66934705P 2005-04-08 2005-04-08
US60/669,347 2005-04-08
PCT/US2006/013473 WO2006110745A2 (fr) 2005-04-08 2006-04-10 Anticorps anti-psma conjugues

Publications (1)

Publication Number Publication Date
CA2603847A1 true CA2603847A1 (fr) 2006-10-19

Family

ID=37087639

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002603847A Abandoned CA2603847A1 (fr) 2005-04-08 2006-04-10 Anticorps anti-psma conjugues

Country Status (5)

Country Link
EP (1) EP1871810A2 (fr)
JP (1) JP2008535865A (fr)
AU (1) AU2006235421A1 (fr)
CA (1) CA2603847A1 (fr)
WO (1) WO2006110745A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2117604A2 (fr) * 2007-01-11 2009-11-18 Immunomedics, Inc. Procédés et compositions pour un marquage par f-18 amélioré de protéines, peptides et autres molécules
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US9028800B2 (en) 2007-01-11 2015-05-12 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3184539A3 (fr) 2001-10-23 2017-09-13 PSMA Development Company L.L.C. Anticorps contre le psma
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
EP1726650A1 (fr) * 2005-05-27 2006-11-29 Universitätsklinikum Freiburg Anticorps monoclonaux et fragments d'anticorps monocaténaires contre l'antigène spécifique de surface membranaire de la prostate
GB0624587D0 (en) * 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
EP2326350B1 (fr) 2008-09-08 2013-09-04 Psma Development Company, L.L.C. Composés pour tuer des cellules cancéreuses exprimant psma et résistantes au taxane
EP3495000A1 (fr) * 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Procédés et kits pour le diagnostic du cancer et la prédiction d'une valeur thérapeutique
WO2016130819A2 (fr) * 2015-02-11 2016-08-18 Emergent Product Development Seattle Llc Compositions et méthodes de polythérapie combinées à des protéines se liant à l'antigène membranaire spécifique de la prostate
KR20190090394A (ko) * 2016-11-30 2019-08-01 메모리얼 슬로안 케터링 캔서 센터 억제제-작용화된 초소형 나노입자 및 이의 방법
CA3050085A1 (fr) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Conjugues de surface cellulaire et compositions cellulaires et methodes associees
JP7284707B2 (ja) 2017-04-07 2023-05-31 ジュノー セラピューティクス インコーポレイテッド 前立腺特異的膜抗原（ｐｓｍａ）またはその改変型を発現する操作された細胞および関連方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE337011T1 (de) * 2001-02-07 2006-09-15 Beth Israel Hospital Modifizierte psma-liganden und deren verwendung
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
WO2004058309A1 (fr) * 2002-12-23 2004-07-15 Human Genome Sciences, Inc. Conjugue neutrokine-alpha, complexe neutrokine-alpha, et leurs utilisations
AU2004263136A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
CA2540621A1 (fr) * 2003-11-19 2005-06-09 Barnes-Jewish Hospital Apport ameliore d'un medicament

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2117604A2 (fr) * 2007-01-11 2009-11-18 Immunomedics, Inc. Procédés et compositions pour un marquage par f-18 amélioré de protéines, peptides et autres molécules
EP2117604A4 (fr) * 2007-01-11 2013-11-20 Immunomedics Inc Procédés et compositions pour un marquage par f-18 amélioré de protéines, peptides et autres molécules
US8889100B2 (en) 2007-01-11 2014-11-18 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US9028800B2 (en) 2007-01-11 2015-05-12 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US9115172B2 (en) 2007-01-11 2015-08-25 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules

Also Published As

Publication number Publication date
WO2006110745A3 (fr) 2007-07-26
JP2008535865A (ja) 2008-09-04
WO2006110745A2 (fr) 2006-10-19
EP1871810A2 (fr) 2008-01-02
AU2006235421A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
CA2603847A1 (fr) Anticorps anti-psma conjugues
JP6185716B2 (ja) 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体
US7420041B2 (en) Cytotoxicity mediation of cells evidencing surface expression of TROP-2
CA2419270C (fr) Anticorps monoclonal ds6 et ses procedes d'utilisation
US20090098046A1 (en) Combination Cancer Therapy with Anti-PSMA Antibodies
JP2005527488A (ja) Ｍｅｔを発現し、肝細胞増殖因子と結合する腫瘍のモノクローナル抗体画像化および治療
US20040265930A1 (en) Monoclonal antibody 7H11 reactive with human cancer
US20090022722A1 (en) Cytotoxicity mediation of cells evidencing surface expression of CD59
KR20140085569A (ko) 치료제 및 이의 용도
CN101189266A (zh) 显示cd63表面表达的细胞毒性介导
JP2010516629A (ja) 癌性疾患修飾抗体
JP2010516630A (ja) 癌性疾患修飾性抗体
US11396538B2 (en) Antibodies to centrin-1, methods of making, and uses thereof
JPH03188099A (ja) 新規な腫瘍関連抗原
JP2010509244A (ja) 癌性疾患修飾抗体
CN118159558A (zh) 抗dll3抗体和其用途
JP2010509245A (ja) 癌性疾患修飾抗体

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20110411